Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
在中国，一项随机、双盲、安慰剂对照的II期临床试验评估了mRNA疫苗和三种基于平台的COVID-19疫苗作为第三剂（在接种两剂CoronaVac疫苗后）的免疫原性、持久性和安全性。
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2022.101680
Zhang, Yuemiao; Ma, Xupu; Yan, Guanghong; Wu, Ying; Chen, Yanli; Zhou, Zumi; Wan, Na; Su, Wei; Liu, Feng-Wei; Dai, Mu-Xian; Yang, Mei; Li, Chunmei; Yu, Xuanjing; Zhang, Liang; Wang, Zhongfang; Zhou, Tai-Cheng; You, Dingyun; Wei, Jia; Zhang, Zijie
